Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

This study aims to determine the safety and tolerability of combined Atezolizumab, stereotactic body radiation therapy (SBRT), and surgical resection of pulmonary metastases in patients with pulmonary recurrence of osteosarcoma

Trial Details

NCT ID
NCT06492954
Phase
PHASE1
Sponsor
Emory University
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Surgical Resection
  • Stereotactic Body Radiation Therapy (SBRT)
  • Atezolizumab
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Participants must have had histologic verification of osteosarcoma at the original diagnosis or relapse
  • Participants must be in first or greater relapse of osteosarcoma
  • Recurrence must be limited to the lung but can be unilateral or bilateral
  • All pulmonary nodules must be resectable as determined by the institutional surgeon. Resectable pulmonary nodules are defined as nodules that can b…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →